Vivo Capital’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Vivo Capital’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-1,151,622	Closed	-$17.6M	–	64
2020 Q3	$17.6M	Hold	1,151,622	–	–	1.02%	27
2020 Q2	$29.3M	Buy	1,151,622 +392,572	+52%	+$8.2M	2.1%	11
2020 Q1	$11.8M	Buy	+759,050	New	+$11.9M	1.06%	27
2019 Q3	–	Sell	-843,478	Closed	-$11.4M	–	21
2019 Q2	$11.4M	Hold	843,478	–	–	1.07%	26
2019 Q1	$15.2M	Buy	843,478 +578,600	+218%	+$11.2M	1.52%	17
2018 Q4	$7.44M	Hold	264,878	–	–	0.95%	28
2018 Q3	$6.75M	Buy	264,878 +78,805	+42%	+$1.53M	0.68%	30
2018 Q2	$3.23M	Buy	+186,073	New	+$3.37M	0.42%	33

Other funds holding KNSA

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Vivo Capital's KNSA Position: Q4 2020 in Review

Vivo Capital sold out of Kiniksa Pharmaceuticals (KNSA) in Q4 2020, closing a stake of 1,151,622 shares — an estimated $17.6M sold.

Vivo Capital first reported a position in KNSA in Q2 2018 and held it in 8 quarters. The position peaked at $29.3M in Q2 2020. 108 funds tracked by Wall St. Rank hold KNSA as of Q4 2020.

Vivo Capital reported no remaining Kiniksa Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Vivo Capital sold 1,151,622 Kiniksa Pharmaceuticals shares in Q4 2020, an estimated $17.6M.
Vivo Capital first reported a position in Kiniksa Pharmaceuticals in Q2 2018 and held it in 8 quarters.
Vivo Capital's Kiniksa Pharmaceuticals position peaked at $29.3M in Q2 2020.
108 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q4 2020.

Based on Vivo Capital's 13F filing for Q4 2020, filed 16 Feb 2021.